Trial Profile
To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Tianjin CanSino Biotechnology
- 07 Feb 2023 Status changed from active, no longer recruiting to completed.
- 28 Oct 2022 Planned End Date changed from 1 Aug 2022 to 1 Dec 2022.
- 28 Oct 2022 Status changed from recruiting to active, no longer recruiting.